Pfizer’s Elrexfio gets EC nod for relapsed and refractory multiple myeloma
The EC approval was based on findings from cohort A of the Phase 2 MagnetisMM-3 study in which…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
11 Dec 23
The EC approval was based on findings from cohort A of the Phase 2 MagnetisMM-3 study in which…
11 Dec 23
This move towards localizing the manufacturing of Sanofi's Clexane adapts to changing market dynamics and enhancement of industrial…
08 Dec 23
The current partnership follows Bayer’s recent alliance with UK-based diagnostic testing company Hurdle, focused on Hurdle’s saliva-based biological…
08 Dec 23
The biosimilar is the second US FDA-approved medication for Bio-Thera and the second biosimilar researched, developed, and produced…
07 Dec 23
Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and…
06 Dec 23
OVX836 has already been evaluated in several Phase 2 clinical trials against seasonal influenza with initial signals of…
05 Dec 23
The Acquisition provides the opportunity to add approximately ZAR 1.8 billion of annual sales to the Aspen Group
05 Dec 23
Collaboration designed to improve health outcomes by enabling expanded access to HIV testing and support services in Nigeria
05 Dec 23
If approved, tradipitant will be the first novel drug to be approved by the FDA for the treatment…
04 Dec 23
Everest plans to contribute to the ongoing global Phase 2b PALIZADE trial of zetomipzomib in active lupus nephritis